These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 25636714)

  • 1. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
    Kappos L; Mehling M; Arroyo R; Izquierdo G; Selmaj K; Curovic-Perisic V; Keil A; Bijarnia M; Singh A; von Rosenstiel P
    Neurology; 2015 Mar; 84(9):872-9. PubMed ID: 25636714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.
    Boulton C; Meiser K; David OJ; Schmouder R
    J Clin Pharmacol; 2012 Dec; 52(12):1879-90. PubMed ID: 22174429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
    Mehling M; Hilbert P; Fritz S; Durovic B; Eichin D; Gasser O; Kuhle J; Klimkait T; Lindberg RL; Kappos L; Hess C
    Ann Neurol; 2011 Feb; 69(2):408-13. PubMed ID: 21387383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACP Journal Club. In multiple sclerosis, use of fingolimod reduced immune responses to influenza and tetanus booster vaccines.
    Absher JR
    Ann Intern Med; 2015 Jun; 162(12):JC8. PubMed ID: 26075785
    [No Abstract]   [Full Text] [Related]  

  • 7. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
    Goldman MD; Naismith RT
    Neurology; 2015 Mar; 84(9):864-5. PubMed ID: 25636716
    [No Abstract]   [Full Text] [Related]  

  • 12. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
    Francis G; Kappos L; O'Connor P; Collins W; Tang D; Mercier F; Cohen JA
    Mult Scler; 2014 Apr; 20(4):471-80. PubMed ID: 23950550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.
    Metze C; Winkelmann A; Loebermann M; Hecker M; Schweiger B; Reisinger EC; Zettl UK
    CNS Neurosci Ther; 2019 Feb; 25(2):245-254. PubMed ID: 30044050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
    Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
    JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.